{
    "clinical_study": {
        "@rank": "65369", 
        "arm_group": {
            "arm_group_label": "saline", 
            "description": "Saline administration to patients with idiopathic Parkinson's disease (PD) of moderate severity, who have previously been treated with sNN0031"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to document the long-term safety and tolerability after\n      intracerebroventricular (ICV) administration of sNN0031 (PDGF-BB) in patients who\n      participated in study sNN0031-001"
        }, 
        "brief_title": "A Follow-up Study on Safety and Tolerability of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previous participation in study sNN0031-001 with completion of 12 study weeks without\n             development of clinically significant safety concerns, defined as being any\n             drug-related or device related serious adverse event that resulted in premature\n             termination of treatment or a medical device incident that could not be resolved\n             during the conduct of study sNN0031-001\n\n          -  The patient has a diagnosis of idiopathic PD\n\n          -  The patient has been given written and verbal information about the follow-up study,\n             has had the opportunity to ask questions about the study, and understands the time\n             and procedural commitments\n\n          -  The patient has provided written informed consent to participate in the follow-up\n             study\n\n        Exclusion Criteria:\n\n          -  The patient has been included or participates in another clinical study after\n             participation in Study sNN0031-001\n\n          -  The patient has, since participation in study sNN0031-001, had functional\n             neurosurgical treatment for PD (e.g., deep brain stimulation).\n\n          -  Patients will only be excluded from participation in the event of a laboratory test\n             abnormality that is indicative of a medical condition requiring treatment which, in\n             the opinion of the investigator, is not compatible with participation in the present\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "30 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients diagnosed with idiopathic PD of moderate severity who have completed\n        participation in study sNN0031-001."
            }
        }, 
        "enrollment": {
            "#text": "11", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01807338", 
            "org_study_id": "sNN0031-002"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lund", 
                    "country": "Sweden", 
                    "zip": "221 85"
                }, 
                "name": "Department of Neurology, Sk\u00e5ne University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Follow-up Study on Safety and Tolerability and Pharmacodynamic Effect, of Patients With Idiopathic Parkinson's Disease (PD) of Moderate Severity, Who Have Previously Been Treated With sNN0031, Using an Implanted Catheter and a SynchroMed\u00ae II Pump", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01807338"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "NeuroNova AB", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Medtronic", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "TFS Trial Form Support", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "NeuroNova AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "March 2013"
    }
}